251 related articles for article (PubMed ID: 19232755)
1. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
3. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
[TBL] [Abstract][Full Text] [Related]
4. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
[TBL] [Abstract][Full Text] [Related]
5. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P
Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072
[TBL] [Abstract][Full Text] [Related]
6. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
[TBL] [Abstract][Full Text] [Related]
7. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
[TBL] [Abstract][Full Text] [Related]
8. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
[TBL] [Abstract][Full Text] [Related]
9. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
[TBL] [Abstract][Full Text] [Related]
10. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR;
Diabetes Care; 2008 May; 31(5):982-8. PubMed ID: 18235048
[TBL] [Abstract][Full Text] [Related]
11. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
12. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Martín-Ventura JL; Tuñon J; Duran MC; Blanco-Colio LM; Vivanco F; Egido J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S189-93. PubMed ID: 17130260
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
[TBL] [Abstract][Full Text] [Related]
16. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Preston RA; Harvey P; Herfert O; Dykstra G; Jukema JW; Sun F; Gillen D
J Clin Pharmacol; 2007 Dec; 47(12):1555-69. PubMed ID: 18048574
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Manisty C; Mayet J; Tapp RJ; Sever PS; Poulter N; McG Thom SA; Hughes AD;
Hypertension; 2009 Nov; 54(5):1009-13. PubMed ID: 19720956
[TBL] [Abstract][Full Text] [Related]
20. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
Hobbs FD; Gensini G; Mancini GB; Manolis AJ; Bauer B; Böhler S; Genest J; Feldman R; Harvey P; Jenssen TG; Metcalfe M; da Silva PM;
Int J Cardiol; 2006 Jun; 110(2):242-50. PubMed ID: 16338012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
